Affirmed Therapeutics BV (NASDAQ:AFMD) shares saw an uptick in trading volume on Wednesday . 139,855 shares traded hands during trading, an increase of 41% from the previous session’s volume of 99,512 shares.The stock last traded at $3.16 and had previously closed at $2.89.

Several brokerages have recently issued reports on AFMD. Jefferies Group lowered their price target on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating on the stock in a research report on Thursday, May 19th. BMO Capital Markets began coverage on Affirmed Therapeutics BV in a research report on Monday, April 11th. They set an “outperform” rating and a $7.00 price target on the stock. Leerink Swann cut Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 19th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Affirmed Therapeutics BV in a research report on Wednesday, May 18th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Affirmed Therapeutics BV presently has an average rating of “Buy” and an average price target of $9.46.

The firm’s 50-day moving average price is $2.82 and its 200 day moving average price is $3.47. The firm’s market cap is $106.96 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its earnings results on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.08. The firm earned $1.90 million during the quarter, compared to analyst estimates of $1.88 million. The business’s quarterly revenue was down 24.0% compared to the same quarter last year. Analysts expect that Affirmed Therapeutics BV will post ($1.06) EPS for the current fiscal year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.